Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer

Linderholm, Barbro; Hellborg, Henrik; Johansson, Ulla; Skoog, Lambert; Lehtiö, Janne

doi:10.1007/s10549-010-1252-x

Cited by 19 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…p-ERK was detected in 73% of the tumor specimens, consistent with data reporting significant p-ERK expression in 69 to 96% of breast tumors (11,31,32). A low expression rate (35%) was only reported in one cohort (33).…”

Section: Discussionsupporting

confidence: 88%

Expression and activation of P38 MAP kinase in invasive ductal breast cancers: Correlation with expression of the estrogen receptor, HER2 and downstream signaling phosphorylated proteins

Merlin¹,

Harlé²,

Lion³

et al. 2013

Oncology Reports

View full text Add to dashboard Cite

Abstract. MAP kinase signaling proteins have major implications in the molecular oncogenesis of breast cancers and have been extensively investigated as putative targets for therapy. This study reports the investigation of the expression of P38 MAPK and its phosphorylated form (p-P38 MAPK) in clinical specimens of invasive breast carcinomas and their correlation with estrogen receptor (ER) and HER2 expression, as well as MAPK and PI3 kinase-AKT pathway signaling phosphorylated proteins. Expression levels of P38 MAPK and p-P38 MAPK as well as p-AKT, p-GSK3β, p-S6 kinase, p-MEK1 and p-ERK1/2 were quantitatively assessed using multiplex bead immunoassay in frozen specimens from 45 invasive ductal breast cancers. Twenty-nine specimens were ER + , 15 were HER2 + and 10 were triple-negative breast cancers (TNBCs). P38 MAPK was found to be expressed in all tumor specimens and was significantly (P= 0.002) overexpressed in ER + tumors. P38 MAPK expression was lower in TNBCs than in all of the other tumors.

show abstract

Section: Discussionsupporting

confidence: 88%

Expression and activation of P38 MAP kinase in invasive ductal breast cancers: Correlation with expression of the estrogen receptor, HER2 and downstream signaling phosphorylated proteins

Merlin¹,

Harlé²,

Lion³

et al. 2013

Oncology Reports

View full text Add to dashboard Cite

show abstract

“…As can be seen from the plot higher VEGFR-2 protein expression was significantly associated with reduced disease-free survival (D, P = 0.0437). tissues were detected in larger, G3 tumors, and in distant metastases [27]. Furthermore, higher VEGFR-2 expression was associated with the presence of metastases in patients with renal cancer [28], thyroid carcinomas [29], and melanomas [30], supporting the idea that VEGFR-2 participate in the progression of several human cancers.…”

Section: Variablementioning

confidence: 67%

Cyclin I correlates with VEGFR-2 and cell proliferation in human epithelial ovarian cancer

Cybulski

Jarosz

Nowakowski

et al. 2012

Gynecologic Oncology

View full text Add to dashboard Cite

“…The original cohort includes tumour homogenates from 404 patients and which has been described in detail elsewhere where data on histological grade and HER2 also are found44. The TMA used in this study consisted of 45 available paraffin-embedded tumours.…”

Section: Methodsmentioning

confidence: 99%

Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer

et al. 2013

Self Cite

View full text Add to dashboard Cite

About one-third of oestrogen receptor alpha-positive breast cancer patients treated with tamoxifen relapse. Here we identify the nuclear receptor retinoic acid receptor alpha as a marker of tamoxifen resistance. Using quantitative mass spectrometry-based proteomics, we show that retinoic acid receptor alpha protein networks and levels differ in a tamoxifen-sensitive (MCF7) and a tamoxifen-resistant (LCC2) cell line. High intratumoural retinoic acid receptor alpha protein levels also correlate with reduced relapse-free survival in oestrogen receptor alpha-positive breast cancer patients treated with adjuvant tamoxifen solely. A similar retinoic acid receptor alpha expression pattern is seen in a comparable independent patient cohort. An oestrogen receptor alpha and retinoic acid receptor alpha ligand screening reveals that tamoxifen-resistant LCC2 cells have increased sensitivity to retinoic acid receptor alpha ligands and are less sensitive to oestrogen receptor alpha ligands compared with MCF7 cells. Our data indicate that retinoic acid receptor alpha may be a novel therapeutic target and a predictive factor for oestrogen receptor alpha-positive breast cancer patients treated with adjuvant tamoxifen.

show abstract

Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer

Abstract: endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer. Breast Cancer Research and Treatment, Springer Verlag, 2010, 125 (2)

Cited by 19 publications

References 29 publications

Expression and activation of P38 MAP kinase in invasive ductal breast cancers: Correlation with expression of the estrogen receptor, HER2 and downstream signaling phosphorylated proteins

Expression and activation of P38 MAP kinase in invasive ductal breast cancers: Correlation with expression of the estrogen receptor, HER2 and downstream signaling phosphorylated proteins

Cyclin I correlates with VEGFR-2 and cell proliferation in human epithelial ovarian cancer

Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer

Contact Info

Product

Resources

About